Xcout Intel
Gene Editing Pioneer Sangamo
Sangamo Therapeutics Inc. is a clinical-stage biotechnology company and a pioneering gene editing firm. The company recently filed for Chapter 11 bankruptcy and agreed to sell its assets.
Subscribe to see Gene Editing Pioneer Sangamo’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Gene Editing Pioneer Sangamo at a glance
Gene Editing Pioneer Sangamo is a biotech company headquartered in United States. Xcout tracks 15 named people at Gene Editing Pioneer Sangamo, including Sandy Macrae (Chief Executive Officer).
Gene Editing Pioneer Sangamo leadership
- Sandy MacraeChief Executive Officer
- Nikunj JainInterim Chief Financial Officer
- Phillip RamseyChief Technical Officer
- Nathalie Dubois-StringfellowChief Development Officer
- Scott WilloughbyChief Legal Officer & Corporate Secretary
- Stephanie J. SeilerHead of Business Development & Alliance Management
9 more named people on record for Gene Editing Pioneer Sangamo, with roles, board committees and tenure — see the full roster →
Get Gene Editing Pioneer Sangamo's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Gene Editing Pioneer Sangamo in Xcout Intel
- 15 named people with titles, LinkedIn and board committees
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access